共查询到20条相似文献，搜索用时 15 毫秒
1.
2.
S. Achargui A. Zidouh S. Abirou F.Z. Merhfour S. Monsif S. Amahrouch A. El Ghobre M. El Halhali H. Temmara A. El Hryfy M. Motqi A. Satty M. Kandili M. Aghri K. Hajjout M. Benajiba 《Transfusion Clinique et Biologique》2017,24(4):422-430
Red blood cell immunization can lead to delays or even an impasse in a transfusion.
Objectives
Determine the specificities of the most common of alloantibodies and their associations to correct management of red blood cell transfused.Methods and materials
A retrospective study between 2013 and 2015 in immunohematology laboratories at the Blood Transfusion Center of Rabat in Morocco. The following data were studied: frequency, specificities of alloantibodies, blood group involved in alloimmunization and difficult of management of transfusion in case with association of alloantibodies.Results
Five hundred of alloantibodies were identified in 425 people (372 patients/pregnant women and 53 blood donors). The alloantibodies were directed against the following antigen: RH1 (50.8 %), RH3 (11.4 %), KEL 1 (8.2 %), RH2 (7.6 %), RH4 (4.6 %), MNS1 (4 %), MNS3 (2.6 %), Jka (2.4 %) and Fya (2.2 %). Only one alloantibody was identified in 85 % of cases. In 15 %, at least, two alloantibodies were found. The most common associations were directed against: anti-(D + C) (25), anti-(E + K) (4), anti-(E + c) (3) and anti-(D + C + E) (3). The rhesus system is the most involved in alloimmunization. Frequency of specific associations of alloantibodies was identified: Fya?/Jkb? (18.23 %), Fyb?/Jkb? (11.7 %), Jka?/S? (8.70 %), Jka?/Fyb? (5.20 %), Fyb?/s? (3.40 %) and Fyb?/Jkb?/s? (0.85 %).Conclusions
Red blood cell immunization is a serious problem in transfused patients. This study proves the data of literature, the interest of using RH-Kel1 red cell units compatibles among women in age to procreate and for the transfused patients to reduce the rate of immunization. Associations of antibodies with low frequency suggest a promotion of donation. 相似文献3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
A.-C. Martin A. Godier D.M. Smadja L. Mauge A.-M. Fischer 《Transfusion Clinique et Biologique》2017,24(3):154-159
Direct oral anticoagulants (DOAC) are indicated for stroke prevention in atrial fibrillation and for the prevention and treatment of venous thromboembolism. As any anticoagulant, they are associated with a bleeding risk. Management of DOAC-induced bleeding is challenging. Idarucizumab, antidote for dabigatran, is currently available and is part of the therapeutic strategy, whereas antidotes for anti-Xa agents are under development. Activated or non-activated prothrombin concentrates are proposed, although their efficacy to reverse DOAC is uncertain. We propose an update on DOAC-associated bleeding management, integrating the availability of idarucizumab and the critical place of DOAC concentration measurements. 相似文献
14.
15.
I. Maaloul O. Laaroussi I. Jedidi L. Sfaihi S. Kmiha T. Kamoun H. Aloulou M. Hachicha 《Transfusion Clinique et Biologique》2018,25(1):14-18
Aim
Our objectives were to assess the management of patients with major thalassemia and identify the various complications and monitoring means.Patients and methods
A retrospective study was conducted on 26 β-thalassemic patients in the department of paediatrics, Hédi Chaker hospital, Sfax, Tunisia during a period of 25 years (from 1 January 1990 to 31 December 2014).Results
The mean age of the beginning of transfusion was 11.5 months. That was with phenotyped red blood cells but not leukodepleted blood. Twenty-three patients received chelation. Before 2001, all patients received deferoxamine, poor adherence to this treatment was observed in 66% of cases. It was replaced by deferiprone since 2006 and deferasirox since 2009. A combination of 2 or 3 chelators was indicated for four patients. A total splenectomy was performed in 10 cases patients; it was due to hypersplenism. The bone marrow transplant was performed for one patient at the age of 9 year but it was rejected. Many complications were detected: endocrine complications (19 cases), immune complications (9 cases), gallbladder stones (5 cases), cardiac complications (4 cases), osteoporosis (3 cases), infectious complications (3 cases) and thromboembolic complications (2 cases). We noted some side effects related to chelation therapy in twelve cases. Four patients were dead.Conclusion
Improving the medical care of homozygous β-thalassemic children requires adherence to transfusion regimen and chelation therapy. Bone marrow transplantation remains the only possible curative therapy, which must be promoted in our country. 相似文献16.
17.
18.
19.